“We have to watch closely whether the huge proceeds are actually predominantly invested [in the development of new drugs and therapies]. Biontech, Moderna and above all Pfizer want to maximize their profits and also serve their shareholders from this,” says IBES director Prof. Dr. Markus Scholz in an interview with Jürgen Salz and Silke Wettach of the renowned German business magazine Wirtschaftswoche. The background was formed by the current orders for additional Covid 19 vaccine doses from the EU Commission. Here, some vaccine manufacturers had increased their prices compared to the previous year, in some cases significantly.
You can read the article here: https://www.wiwo.de/my/unternehmen/industrie/corona-impfstoff-warum-die-eu-bei-biontechs-preiserhoehungen-keine-wahl-hat/27595366.html